Compare prices and buy Tesamorelin + Ipamorelin Blend from 23 research peptide vendors - also called suppliers or sources. Updated daily.
A two-peptide growth hormone-axis blend pairing tesamorelin, a GHRH analog with an FDA approval, with ipamorelin, a ghrelin-receptor agonist with none. The two act at separate pituitary receptors, but the pairing is a market convention rather than a demonstrated pharmacological one, and no registered or published study has tested them together. Splits vary by vendor and are usually tesamorelin-heavy. For research purposes only.
For research purposes only. Not medical advice.
The tesamorelin + ipamorelin blend puts two growth hormone-axis peptides in one vial. It is a mixture, so it has no CAS number of its own, and no pharmacopeia recognizes the combination as a substance.
Tesamorelin is the 44-residue sequence of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoyl group on its N-terminal tyrosine. Its FDA label reports that in vitro it binds and stimulates human GHRH receptors with potency similar to the native hormone. Ipamorelin is a synthetic pentapeptide that acts at a different receptor, the ghrelin receptor GHS-R1a. Raun and colleagues called it the first selective growth hormone secretagogue in 1998 because, unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol in swine. Both act on the pituitary cells that make growth hormone.
Vendors do not agree on the split. Ratios indexed here include 10/3, 11/3, 13/3, 10/5, 10/10 and 5/5 (milligrams of tesamorelin, then ipamorelin), and some listings state only a total. PeptideScouter records the vial total, so a 10/3 vial is 13 mg and a 13/3 vial is 16 mg. Titles mislead too. One storefront's "10mg" blend holds 10 mg of tesamorelin plus 3 mg of ipamorelin, while a "13mg/3mg" title elsewhere means a 16 mg vial.
Neither component name covers two different molecules, as CJC-1295 does, so the ambiguity in this blend is the split and the salt form. The Egrifta labels state vial contents as tesamorelin free base next to a larger acetate-salt figure, and research listings rarely say which one their milligrams count. A certificate of analysis that reports each component separately is the only check on either.
By molecule count the balance reverses. Tesamorelin weighs about 5,136 daltons against ipamorelin's 712, so a 10/3 vial holds roughly twice as many ipamorelin molecules.
The pairing borrows the rationale behind the CJC-1295 + ipamorelin blend. In 1990, Bowers and colleagues reported in the Journal of Clinical Endocrinology and Metabolism that a growth hormone-releasing peptide given with GHRH released more growth hormone in healthy men than either did alone. The GHRH in that study was the native 44-residue hormone, the sequence tesamorelin modifies, but the peptide was GHRP-6, and the outcome was acute growth hormone release after an intravenous injection. Neither tesamorelin nor ipamorelin was tested.
A search of ClinicalTrials.gov and Europe PMC on October 20, 2026 found no registered or published study giving tesamorelin with ipamorelin or any other GHRP. Tesamorelin's own two Phase 3 trials, published in 2007 and 2010, tested it alone in HIV-infected adults with excess abdominal fat. The pairing is a market convention rather than a pharmacological one.
The FDA approved Theratechnologies' Egrifta on November 10, 2010, and approved Egrifta WR, a new formulation, on March 25, 2025. As of October 2026, DailyMed carries current labels for Egrifta SV and Egrifta WR, both indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Both labels add that the product is not indicated for weight loss management and that its long-term cardiovascular safety has not been established. Tesamorelin's 44 residues exceed the 40-amino-acid line in the FDA's definition of a protein, and Drugs@FDA records that its application was deemed a biologics license on March 23, 2020. That approval sets its status, and tesamorelin appears in neither table of the FDA's Category 2 page.
Ipamorelin has no FDA approval, and its only registered interventional trials were two Phase 2 studies in postoperative ileus.
No approved product contains both peptides. The World Anti-Doping Agency's 2026 Prohibited List names both under S2.2.4, prohibited at all times, and its 2027 list keeps them there.
Tesamorelin is the larger share in most vials, so the blend's per-milligram price mostly tracks tesamorelin's. At the same vial size, ipamorelin usually indexes cheaper per milligram than tesamorelin, so an even split pulls the blend's figure further toward ipamorelin's than a 10/3 split does. Two blend listings are comparable only once their splits are known.
Vendors abbreviate the name as Tesa/IPA, Tesa/Ipa or Tesa/Ipamo, with tesamorelin first. Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
No. No FDA-approved product contains both peptides. Tesamorelin is approved only as Theratechnologies' Egrifta products, currently Egrifta SV and Egrifta WR, for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, and both labels state that the product is not indicated for weight loss management. Ipamorelin has no FDA approval. The approval covers those labeled products only and does not extend to research-grade tesamorelin or to a vial that adds ipamorelin. The blend sold by research peptide vendors is offered for laboratory research use only and not for human consumption.
It depends on the vendor. Splits indexed by PeptideScouter include 10 mg of tesamorelin with 3 mg of ipamorelin, 11 with 3, 13 with 3, 10 with 5, 10 with 10 and 5 with 5, and some listings state only the total. Tesamorelin is the larger share in most vials. PeptideScouter records the combined total as the vial size, so a 10 plus 3 vial appears as 13 mg. Product titles are an unreliable guide, since one may quote only the tesamorelin amount while another lists both components, and a certificate of analysis that reports each component separately is the only reliable check.
No registered or published study turned up in a search of ClinicalTrials.gov and Europe PMC on October 20, 2026. The result usually cited for pairing the two receptor classes is a 1990 study by Bowers and colleagues in healthy men, in which a growth hormone-releasing peptide given with growth hormone-releasing hormone released more growth hormone than either did alone. That study used GHRP-6 and the native hormone, so neither tesamorelin nor ipamorelin was in it, and tesamorelin's own Phase 3 trials tested it alone. No controlled trial has evaluated the combination sold in these vials.
A CAS Registry Number identifies a single substance, and the blend is a mixture of two. Each component has its own number. Tesamorelin is 218949-48-5, molecular formula C221H366N72O67S, and ipamorelin is 170851-70-4, C38H49N9O5, and both match the records in PubChem and the FDA's Global Substance Registration System. A certificate of analysis for the blend should identify and quantify each component separately.
Yes. The World Anti-Doping Agency's 2026 Prohibited List names tesamorelin among growth hormone-releasing hormone analogues and ipamorelin among growth hormone secretagogues, both in section S2.2.4, and the S2 class is prohibited at all times, in and out of competition. The 2027 list, which takes effect on January 1, 2027, keeps both entries. Tesamorelin's FDA approval does not remove it from the list, which names it explicitly.
Tesamorelin + Ipamorelin Blend is sold by 23 research peptide vendors indexed on PeptideScouter, with 30 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
22 of the 23 indexed vendors currently have Tesamorelin + Ipamorelin Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Renova Peptides currently lists Tesamorelin + Ipamorelin Blend at $4.17/mg, the lowest listed price across 23 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.70/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 23 vendors listing Tesamorelin + Ipamorelin Blend publish a PeptideScouter code, worth 5% to 20% off. Applied, the lowest effective price falls from $3.00/mg listed to $2.70/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Tesamorelin + Ipamorelin Blend ranges from $3.00/mg to $18.00/mg across 30 listings from 23 research peptide vendors, normalized to USD per milligram and refreshed daily.
23 research peptide vendors currently list Tesamorelin + Ipamorelin Blend on PeptideScouter, with 22 in stock right now. We track 30 listings across size and kit variants.
